世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の尿失禁治療市場 2019-2023年

Global Urinary Incontinence Therapeutics Market 2019-2023

IRTNTR30102

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
117

サマリー

この調査レポートは世界の尿失禁治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Urinary Incontinence
Urinary incontinence is any uncontrolled leakage of urine and this market report consists of the therapeutics used for the treatment of the diseases.
Technavio’s analysts forecast the Global Urinary Incontinence Therapeutics Market to grow at a CAGR of 3.12% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the urinary incontinence therapeutics market. To calculate the market size, the report considers the revenue generated from the application of urinary incontinence therapeutics across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, urinary incontinence therapeutics market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Allergan
- Astellas Pharma
- Merck
- Novartis
- Pfizer
Market driver
- Robust pipeline for the development of drugs for urinary incontinence treatment
- For a full, detailed list, view our report

Market challenge
- Patent expiries of drugs
- For a full, detailed list, view our report

Market trend
- Shift toward novel formulations
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Anticholinergic drugs - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- ALLERGAN
- Astellas Pharma
- Merck
- Novartis
- Pfizer
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO

?
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: MoA of anticholinergic drugs
Exhibit 20: Anticholinergic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Anticholinergic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Others - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Growth in geriatric population in various countries of Americas 2007 and 2017 (%)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Prevalence, rate of urinary incontinence among the US residential care facility residents aged 65 and over 2010 (%)
Exhibit 41: Recent approvals of generic drugs
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: ALLERGAN - Vendor overview
Exhibit 49: ALLERGAN - Business segments
Exhibit 50: ALLERGAN - Organizational developments
Exhibit 51: ALLERGAN - Geographic focus
Exhibit 52: ALLERGAN - Segment focus
Exhibit 53: ALLERGAN - Key offerings
Exhibit 54: ALLERGAN - Key customers
Exhibit 55: Astellas Pharma - Vendor overview
Exhibit 56: Astellas Pharma - Business segments
Exhibit 57: Astellas Pharma - Organizational developments
Exhibit 58: Astellas Pharma - Geographic focus
Exhibit 59: Astellas Pharma - Segment focus
Exhibit 60: Astellas Pharma - Key offerings
Exhibit 61: Astellas Pharma - Key customers
Exhibit 62: Merck - Vendor overview
Exhibit 63: Merck - Business segments
Exhibit 64: Merck - Organizational developments
Exhibit 65: Merck - Geographic focus
Exhibit 66: Merck - Segment focus
Exhibit 67: Merck - Key offering
Exhibit 68: Merck - Key customers
Exhibit 69: Novartis - Vendor overview
Exhibit 70: Novartis - Business segments
Exhibit 71: Novartis - Organizational developments
Exhibit 72: Novartis - Geographic focus
Exhibit 73: Novartis - Segment focus
Exhibit 74: Novartis - Key offerings
Exhibit 75: Novartis - Key customers
Exhibit 76: Pfizer - Vendor overview
Exhibit 77: Pfizer - Business segments
Exhibit 78: Pfizer - Organizational developments
Exhibit 79: Pfizer - Geographic focus
Exhibit 80: Pfizer - Segment focus
Exhibit 81: Pfizer - Key offerings
Exhibit 82: Pfizer - Key customers


 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る